The market for obesity treatments and GLP-1 therapies is large and growing, with structural long-term demand. The current market price of Novo Nordisk (EUR 33.1) does not fully reflect this long-term growth potential, leading to an undervaluation compared to the author's calculated fair value (EUR 47.7). Novo Nordisk is undervalued because the market underestimates the size and durability of the obesity drug market, presenting a long-term buying opportunity. Increased competition, pricing pressure from payers, unexpected side effects from GLP-1 drugs, or a slowdown in market adoption could invalidate the thesis.
NVO
HIGH
Mar 15, 22:33
Key Points
['Market underestimates obesity treatment market size.', 'Structural demand for GLP-1 therapies is strong.', "Author's valuation implies ~44% upside.", 'Base case target price: EUR 47.7 per share.']
March 15, 2026 at 22:33